--- title: "LENSAR (NASDAQ:LNSR) Stock Rating Upgraded by Wall Street Zen" type: "News" locale: "en" url: "https://longbridge.com/en/news/296692488.md" description: "Wall Street Zen upgraded LENSAR (NASDAQ:LNSR) from a 'hold' to a 'buy' rating. Other analysts also commented: Weiss Ratings reiterated a 'sell', Lake Street reaffirmed a 'buy' with a $13 target, and BTIG raised its price target to $10 while maintaining a 'buy'. The stock has an average analyst rating of 'Hold' with a consensus target of $11.50. Recent quarterly earnings beat estimates, reporting $0.10 EPS and $16.50 million revenue. Institutional investors, including BNP Paribas and JPMorgan, increased their holdings in recent quarters." datetime: "2026-08-23T05:06:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296692488.md) - [en](https://longbridge.com/en/news/296692488.md) - [zh-HK](https://longbridge.com/zh-HK/news/296692488.md) generator: "portal-rs" --- # LENSAR (NASDAQ:LNSR) Stock Rating Upgraded by Wall Street Zen LENSAR (NASDAQ:LNSR - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Sunday. A number of other equities research analysts also recently commented on the stock. Weiss Ratings reiterated a "sell (d+)" rating on shares of LENSAR in a report on Friday, August 7th. Lake Street Capital reaffirmed a "buy" rating and issued a $13.00 target price on shares of LENSAR in a research note on Thursday, August 13th. Finally, BTIG Research boosted their price target on LENSAR from $9.00 to $10.00 and gave the company a "buy" rating in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $11.50. **Get Our Latest Analysis on LNSR** ## LENSAR Price Performance LENSAR stock opened at $8.68 on Friday. The stock has a market cap of $106.68 million, a price-to-earnings ratio of -26.30 and a beta of 0.89. The firm has a 50 day simple moving average of $6.16 and a 200-day simple moving average of $7.23. LENSAR has a 1-year low of $4.95 and a 1-year high of $12.96. LENSAR (NASDAQ:LNSR - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26. The business had revenue of $16.50 million for the quarter, compared to the consensus estimate of $14.65 million. LENSAR had a negative return on equity of 529.08% and a net margin of 57.57%. ## Hedge Funds Weigh In On LENSAR Large investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets boosted its holdings in shares of LENSAR by 129.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,008 shares of the company's stock valued at $25,000 after purchasing an additional 1,131 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in shares of LENSAR in the 2nd quarter worth $58,000. JPMorgan Chase & Co. raised its position in shares of LENSAR by 584.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,674 shares of the company's stock worth $62,000 after buying an additional 3,991 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in LENSAR in the second quarter valued at $68,000. Finally, Sanctuary Advisors LLC acquired a new position in LENSAR in the second quarter valued at $96,000. Hedge funds and other institutional investors own 40.15% of the company's stock. ## About LENSAR (Get Free Report) LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions. Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment. ## Read More - Five stocks we like better than LENSAR - 2 Biotech Stocks Shaping Up for Major Breakouts - 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs - 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run - Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in LENSAR Right Now? Before you consider LENSAR, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LENSAR wasn't on the list. While LENSAR currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [LNSR.US](https://longbridge.com/en/quote/LNSR.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [JPX.US](https://longbridge.com/en/quote/JPX.US.md) - [JPMO.US](https://longbridge.com/en/quote/JPMO.US.md) - [BK.US](https://longbridge.com/en/quote/BK.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [DRI.US](https://longbridge.com/en/quote/DRI.US.md) - [BK-K.US](https://longbridge.com/en/quote/BK-K.US.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) ## Related News & Research - [LENSAR posts investor presentation highlighting ALLY robotic laser cataract surgery platform](https://longbridge.com/en/news/296134599.md) - [BTIG Research Forecasts Strong Price Appreciation for LENSAR (NASDAQ:LNSR) Stock](https://longbridge.com/en/news/295824844.md) - [JPMorgan debanked Polymarket on regulatory concerns, FT says](https://longbridge.com/en/news/296126726.md) - [JPMorgan Slams Bessent's Bond Market Intervention: Market Will View Treasury As "Lacking Credibility"](https://longbridge.com/en/news/296514467.md) - [4-JPMorgan entity among two firms barred in India over alleged closing auction manipulation](https://longbridge.com/en/news/296427965.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**